Indication
HER2-positive Gastric Cancer
16 clinical trials
28 products
2 drugs
Product
ELVN-002Product
5-FluorouracilClinical trial
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast CancerStatus: Recruiting, Estimated PCD: 2027-01-01
Product
CapecitabineProduct
EribulinProduct
LeucovorinProduct
OxaliplatinProduct
paclitaxelProduct
CT-0508Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesStatus: Terminated, Estimated PCD: 2023-06-02
Product
PembrolizumabClinical trial
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
TebotelimabProduct
margetuximabProduct
RetifanlimabClinical trial
A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
TAC01-HER2Clinical trial
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-08-11
Product
PRS-343Clinical trial
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2Status: Recruiting, Estimated PCD: 2027-04-01
Product
XMT-2056Clinical trial
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-02-07
Product
BI-1607Clinical trial
A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01
Product
CyclophosphamideProduct
ACE1702Product
FludarabineClinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved TherapiesStatus: Completed, Estimated PCD: 2022-01-12
Product
A166Clinical trial
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid TumorsStatus: , Estimated PCD: 2025-12-31
Clinical trial
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
SerplulimabDrug
TrastuzumabProduct
Oxaliplatin + TegafurClinical trial
Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Product
Combination of MVF-HER-2Clinical trial
Disitamab Vedotin Combined With Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive Metastatic Gastric Cancer: A Prospective Phase Ib/II StudyStatus: Recruiting, Estimated PCD: 2025-05-01
Product
Disitamab VedotinClinical trial
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Drug
PD-1 antibodyProduct
FLOTClinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib TrialStatus: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine